Douglas Odea, MD
Internal Medicine · Bartlett, TNNPI 1316974132
Payments from drug & device makers
Across 433 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$866
- AbbVie$847
- Amarin Pharma, Inc.$829
- AstraZeneca$798
- Lilly USA, LLC$745
- Boehringer Ingelheim$386
- plus $2K from 35 others
What the payments were for
- Food & beverage$6,842100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 52 | $866 |
| AbbVie(2 entities) | 66 | $847 |
| Amarin Pharma, Inc. | 55 | $829 |
| AstraZeneca | 45 | $798 |
| Lilly USA, LLC | 42 | $745 |
| Boehringer Ingelheim | 25 | $386 |
| Pfizer | 33 | $351 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $242 |
| Abbott | 9 | $173 |
| Astellas Pharma US Inc | 7 | $115 |
| GSK | 7 | $108 |
| E.r. Squibb & Sons, L.L.C. | 7 | $108 |
| Amgen | 7 | $101 |
| Biotronik Inc. | 1 | $101 |
| Johnson & Johnson | 7 | $95 |
| Kowa Pharmaceuticals America, Inc. | 6 | $94 |
| Gilead | 5 | $81 |
| Bardy Diagnostics, Inc. | 1 | $75 |
| Clarus Therapeutics Inc. | 4 | $65 |
| Mylan Specialty L.p. | 4 | $65 |
| Arbor Pharmaceuticals, Inc. | 3 | $56 |
| Medtronic | 1 | $44 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Ironwood Pharmaceuticals, Inc | 3 | $42 |
| Abiomed | 1 | $41 |
| Ascensia Diabetes Care US Inc. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Recor Medical Inc | 2 | $33 |
| Inogen, Inc. | 2 | $30 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Merck | 2 | $25 |
| Bayer | 2 | $25 |
| Novartis | 1 | $23 |
| Exact Sciences | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Seqirus USA Inc | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,852 in reported general payments places this provider in the 90th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 68 | $73,131 |
| EliquisApixaban | 63 | $60,861 |
| XareltoRivaroxaban | 61 | $54,048 |
| TrulicityDulaglutide | 24 | $49,576 |
| OzempicSemaglutide | 32 | $36,092 |
| JardianceEmpagliflozin | 32 | $28,635 |
| MounjaroTirzepatide | 27 | $27,401 |
| EntrestoSacubitril/Valsartan | 13 | $25,049 |
| JanuviaSitagliptin Phosphate | 21 | $21,744 |
| LinzessLinaclotide | 22 | $19,314 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $14,887 |
| Spiriva RespimatTiotropium Bromide | 21 | $10,820 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $10,220 |
| Atorvastatin Calcium | 456 | $5,314 |
| Tolterodine Tartrate ErTolterodine Tartrate | 45 | $5,221 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $798 | $83,35180 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $745 | $76,97851 claims |
| PfizerEliquis | $351 | $60,86163 claims |
| Johnson & JohnsonXarelto | $95 | $54,04861 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $386 | $39,45553 claims |
| Novo NordiskOzempic | $866 | $36,09232 claims |
| MerckJanuvia, Dulera | $25 | $25,54032 claims |
| NovartisEntresto | $23 | $25,04913 claims |
| AbbVieLinzess | $847 | $19,31422 claims |
| GSKTrelegy Ellipta | $108 | $14,88720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Bartlett
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.